Li M - Search Results

1

Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation.

Cheng H, Wang S, Gao D, Yu K, Chen H, Huang Y, Li M, Zhang J, Guo K. Cheng H, et al. Among authors: li m. Cell Oncol (Dordr). 2023 Apr;46(2):283-297. doi: 10.1007/s13402-022-00749-7. Epub 2022 Dec 1. Cell Oncol (Dordr). 2023. PMID: 36454514

2

HSF1: a mediator in metabolic alteration of hepatocellular carcinoma cells in cross-talking with tumor-associated macrophages.

Liu HT, Huang DA, Li MM, Liu HD, Guo K. Liu HT, et al. Am J Transl Res. 2019 Aug 15;11(8):5054-5064. eCollection 2019. Am J Transl Res. 2019. PMID: 31497221 Free PMC article.

3

HSF1/AMPKα2 mediated alteration of metabolic phenotypes confers increased oxaliplatin resistance in HCC cells.

Shen JH, Chen PH, Liu HD, Huang DA, Li MM, Guo K. Shen JH, et al. Am J Cancer Res. 2019 Nov 1;9(11):2349-2363. eCollection 2019. Am J Cancer Res. 2019. PMID: 31815039 Free PMC article.

4

Effects of LRP1B Regulated by HSF1 on Lipid Metabolism in Hepatocellular Carcinoma.

Li M, Hu J, Jin R, Cheng H, Chen H, Li L, Guo K. Li M, et al. Among authors: li l. J Hepatocell Carcinoma. 2020 Dec 8;7:361-376. doi: 10.2147/JHC.S279123. eCollection 2020. J Hepatocell Carcinoma. 2020. PMID: 33324588 Free PMC article.

5

HSF1 is involved in immunotherapeutic response through regulating APOJ/STAT3-mediated PD-L1 expression in hepatocellular carcinoma.

Cheng H, Wang S, Huang A, Ma J, Gao D, Li M, Chen H, Guo K. Cheng H, et al. Among authors: li m. Cancer Biol Ther. 2023 Dec 31;24(1):1-9. doi: 10.1080/15384047.2022.2156242. Cancer Biol Ther. 2023. PMID: 36482717 Free PMC article.

6

HSP90a promotes the resistance to oxaliplatin in HCC through regulating IDH1-induced cell competition.

Wang S, Cheng H, Huang Y, Li M, Gao D, Chen H, Su R, Guo K. Wang S, et al. Among authors: li m. Biochim Biophys Acta Mol Cell Res. 2024 Mar;1871(3):119680. doi: 10.1016/j.bbamcr.2024.119680. Epub 2024 Jan 26. Biochim Biophys Acta Mol Cell Res. 2024. PMID: 38280407

7

BNIP3-mediated mitophagy boosts the competitive growth of Lenvatinib-resistant cells via energy metabolism reprogramming in HCC.

Wang S, Cheng H, Li M, Gao D, Wu H, Zhang S, Huang Y, Guo K. Wang S, et al. Among authors: li m. Cell Death Dis. 2024 Jul 5;15(7):484. doi: 10.1038/s41419-024-06870-9. Cell Death Dis. 2024. PMID: 38969639 Free PMC article.

8

Ibrutinib combined with low-dose histone deacetylases inhibitor chidamide synergistically enhances the anti-tumor effect in B-cell lymphoma.

Yu H, Mi L, Zhang W, Ye Y, Li M, Hu D, Cao J, Wang D, Wang X, Ding N, Song Y, Zhu J. Yu H, et al. Among authors: li m. Hematol Oncol. 2022 Dec;40(5):894-905. doi: 10.1002/hon.3056. Epub 2022 Aug 24. Hematol Oncol. 2022. PMID: 35975476

9

Effect of infection with hepatitis B virus on the survival outcome of diffuse large B-cell lymphoma in the prophylactic antiviral era.

Nuersulitan R, Li M, Mi L, Wu M, Ji X, Liu Y, Zhao H, Wang G, Song Y, Zhu J, Liu W. Nuersulitan R, et al. Among authors: li m. Front Oncol. 2022 Aug 22;12:989258. doi: 10.3389/fonc.2022.989258. eCollection 2022. Front Oncol. 2022. PMID: 36072805 Free PMC article.

10

Anti-CD47 immunotherapy in combination with BCL-2 inhibitor to enhance anti-tumor activity in B-cell lymphoma.

Li M, Yu H, Qi F, Ye Y, Hu D, Cao J, Wang D, Mi L, Wang Z, Ding N, Ping L, Shu S, Zhu J. Li M, et al. Hematol Oncol. 2022 Oct;40(4):596-608. doi: 10.1002/hon.3009. Epub 2022 May 10. Hematol Oncol. 2022. PMID: 35477179

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75,156 results

Search Page

Filters